PDB57 CONTENT DEVELOPMENT FORA NEW INSTRUMENT TO ASSESS PATIENT AND PARENT PREFERENCE FOR GROWTH HORMONE REPLACEMENT THERAPY DELIVERY DEVICES  by Stephens, JM et al.
ing Pubmed between 2002 and 2007 for studies assessing quality
of life as an outcome due to adherence or compliance. Search
terms included were “Diabetes Mellitus Type 2, Compliance,
Medication Adherence” and various combinations of these
terms. There was no speciﬁc criterion to include or exclude
studies. All studies which ﬁt into the purpose for literature review
were analyzed. Patient education was found to be an intervention
that enhances the quality of life. Use of different drug and drug
delivery methods than conventional drugs were also found to
improve quality of life. Age, gender, and treatment problems
associated with insulin are risk factors for discontinuation and
non-adherence to medications. Older patients were found to be
adherent than younger patients. Forgetting to follow regimen,
disruption of routine and adverse effects were some barriers
reported in the literature. The main strategies for medication
adherence were found to be individualized daily routines,
reminder devices such as a day of the week, pillbox, and use of a
special place. There are not many studies done to date to evaluate
the quality of life as an outcome due to adherence and compli-
ance. Further research in this area will help better the under-
standing of relationship between quality of life as an outcome
due to adherence or compliance.
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DEVELOPMENT OF A CLASSIFICATION SYSTEM FOR
A DIABETES-SPECIFIC PREFERENCE-BASED
MEASURE OF HEALTH
Sundaram M, Smith MJ, Nath C
West Virginia University, Morgantown,WV, USA
OBJECTIVE: To develop a classiﬁcation system (CS) for a
diabetes-speciﬁc preference-based measure of health (PBMH).
METHODS: Plausible attributes for the PBMHwere identiﬁed by
Classical Test Theory, using Factor Analysis of responses
from Type 2 Diabetes patients (n = 385) to the 18-item Audit
of Diabetes-Dependent Quality of Life (ADDQoL). A seven-
member expert panel then provided qualitative input for content.
Three pilot rounds in outpatient and community settings pro-
duced data from people with Type 1 and Type 2 diabetes (n1 = 52,
n2 = 65, n3 = 111) that were analyzed usingModern Test Theory,
based onRaschAnalysis (RA), for 1) ﬁt of selected attributes to the
Rasch Model, and 2) scaling of severity levels for attributes.
RESULTS: Principal Axis Factoring with Promax rotation identi-
ﬁed two plausible attributes from six ADDQoL items. In a struc-
tured survey, experts rated the importance of all ADDQoL and
additionally important items, and suggested attributes that might
be described using sets of related items. A CS was developed
consisting of ﬁve independent attributes, with each question con-
taining a description based on the item content of the respective
attribute and four sentences describing severity levels. Maintain-
ing this format, the wording in the CS was further modiﬁed based
on additional input from experts andRA after each pilot. The ﬁnal
attributes were: Physical Ability & Energy, Relationships, Mood
& Feelings, Enjoyment of Diet, and Satisfaction with Manage-
ment of diabetes. Results of the third pilot indicated Inﬁt and
Outﬁt MNSQ for the ﬁve attributes ranging between 0.88 and
1.10. Person and Item reliabilities were 0.65 and 0.92, while the
respective separation ratios were 1.36 and 3.34. Severity levels
usedwere supported byRating Scale Diagnostics indicated byRA.
CONCLUSION: Results of the statistical analyses indicate that
the PBMH has desired psychometric properties. Research on the
estimation of a utility scoring algorithm and validation testing of
this PBMH is ongoing.
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PREFERENCES FOR ORAL ANTIDIABETIC AGENTS AMONG
PEOPLEWITHTYPE 2 DIABETES
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OBJECTIVE: The objective of this study is to quantify the
strength of preferences and likely adherence to therapy of people
with type 2 diabetes mellitus (T2DM) for outcomes of oral
antidiabetic agents (OADs). METHODS: Currently many of the
available OADs for T2DM are associated with side effects such
as weight gain and nausea and vomiting. Understanding patient
preferences for medications with different attributes is important
for predicting likely adherence to OAD treatments with different
side-effects. We developed a web-based instrument to elicit treat-
ment preferences. Inclusion criteria were people 18 years of age
and older who were insulin-naïve and currently taking OADs to
treat T2DM. The instrument included ten stated-choice trade-off
tasks. Subjects chose between pairs of hypothetical medication
alternatives, each including change in HbA1c levels, number
of mild-to-moderate hypoglycemic events per month, water
retention, weight gain in the ﬁrst six months of treatment, mild
stomach upset, and risk of heart attack. Sample sizes were 200 in
the United States and 200 in the UK. RESULTS: The majority of
subjects were white, married, and female. Subjects were willing
to make tradeoffs between all medication attributes. On average,
subjects would accept signiﬁcant weight gain if the medication
yielded a reduction in HbA1c that resulted in optimal control
(6.5%). However, subjects’ stated adherence was signiﬁcantly
lower for treatments with weight gain, increased heart-attack
risk, or persistent nausea and vomiting. The UK sample was less
tolerant of hypoglycemic events. CONCLUSION: While people
with T2DM believe glucose control is important, medication
side-effects inﬂuence patients’ treatment choices. Efﬁcacy as
measured under controlled, clinical-trial conditions may over-
state actual treatment effectiveness as a result of patient concerns
over OAD side effects.
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OBJECTIVE: Few patient-reported outcome measures for
growth hormone (GH) replacement therapy have been formally
validated and none address preference for a particular delivery
method. Our objective was to formally develop a new instru-
ment to assess child and parent satisfaction with and preference
for GH therapy delivery devices. METHODS: An instrument
item pool was generated by combining the following four steps:
1) thorough literature review to identify relevant domains and
questions, 2) consultation with clinicians knowledgeable about
treatment of GH deﬁciency, 3) identiﬁcation of indicators spe-
ciﬁc to GH delivery devices, and 4) input from families with
children aged 10–16 years receiving GH therapy, including both
new (2 to 12 weeks) and established (12 weeks) users. Struc-
tured feedback forms were completed during cognitive inter-
views with focus groups on relevance of questions, missing
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topics, understandability, and feasibility of use. Based on the
above steps, a preliminary instrument was created for valida-
tion testing. RESULTS: Key themes generated from literature,
clinicians, and families included various aspects of pain, difﬁ-
culty using the device, embarrassment, and time involved
affecting productivity, convenience, and compliance. Two ver-
sions of the preference instrument were created to reﬂect the
child and parent perspectives. A 4-point Likert scale was used
for most questions. The child version included 38 survey items
on clarity of instructions (2), preparation (7), administration
(4), convenience (3), pain (5), embarrassment (2), anxiety (2),
productivity (4), compliance (3), mood (1), and overall satis-
faction (5). All items from the child questionnaire were
included in the parent version, supplemented with ﬁve ques-
tions regarding administration, parent productivity, and parent
overall satisfaction. CONCLUSION: Areas of concern for fami-
lies using GH delivery devices include pain, productivity, and
convenience. This new instrument, which may offer clinicians
and researchers an opportunity to evaluate different device
alternatives for GH replacement therapy, will soon undergo
formal validation testing.
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OBJECTIVE: To assess the association between the DM-39 and
HbA1c in a large insulin clinical trial (acronym: DURABLE)
where HbA1c is a primary efﬁcacy endpoint. METHODS: The
DURABLE trial enrolled insulin-naïve type 2 diabetes patients
then randomized them to lispro mix 75/25 bid or glargine qd.
Trial participants completed the DM-39 at baseline prior to
receiving insulin. The DM-39 is a 39-item diabetes-speciﬁc
PRO measure with 5 domains: Energy/Mobility (15-item), Dia-
betes Control (12-item), Anxiety/Worry (4-item), Social Burden
(5-item), and Sexual Function (3-item). Each domain’s score
ranged from 0–100 with a higher score representing worse
PRO. We used Spearman’s correlation to assess the overall
association with HbA1c. We also conducted analysis of vari-
ance (ANOVA) with pairwise comparisons using Scheffe adjust-
ment to compare the mean scores reported by patients with
baseline HbA1c <8.0% (group A); 8.0–8.9% (B); 9.0–9.9%
(C); and >10% (D). RESULTS: A trial subgroup of 867
patients (mean age = 56.8 years, duration of diabetes = 9.6
years, HbA1c = 8.9%. 42% female, 65% Caucasian) provided
the data. Correlations with HbA1c were low (r range: 0.01–
0.18) with Diabetes Control (r = 0.18), Anxiety/Worry
(r = 0.10), and Social Burden (r = 0.11) resulting in statistically
signiﬁcant correlations (p < 0.01). Overall ANOVA p-values
were statistically signiﬁcant for Diabetes Control (mean scores
for groups A, B, C, and D = 37.5, 39.7, 43.7, and 46.2, respec-
tively, p < 0.001); Anxiety/Worry (41.5, 42.2, 48.5, and 47.0,
p = 0.003); and Social Burden (22.2, 21.6, 25.5, and 28.3,
p < 0.001). Pairwise comparisons were statistically signiﬁcant
for Diabetes Control (A vs. C, A vs. D, and B vs. D); Anxiety/
Worry (A vs. C); and Social Burden (A vs. D and B vs. D).
CONCLUSION: DM-39 is weakly associated with HbA1c.
However, our ﬁndings suggest that some targeted domains (e.g.,
Diabetes Control) may be useful in assessing the changes in
PRO for clinical trials evaluating insulin initiation with a
primary endpoint of HbA1c.
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BEHAVIORS AMONG DIABETES POPULATION IN USA
Guo JD, Root MM, Hu G
Biosignia Inc, Durham, NC, USA
OBJECTIVE: The study evaluated the impact of a doctor’s or a
health professional’s instructions on lifestyle behaviors among
the US adult diabetic population. METHODS: The study popu-
lation was adult diabetic subjects in the latest National Health
and Nutrition Examination Survey (NHANES) 2005–2006.
Multivariate logistic regression was employed adjusting for the
survey design using STATA software. A total of 459 diabetic
subjects aged 18 and over were enrolled, which represented
about 15 million US adults with diabetes. The three dichotomous
categorical independent variables of interest were whether the
subject had been told by their doctor or health professional in the
last year to lower their risk of certain diseases by controlling
weight, by increasing physical activity, or by reducing fat or
calorie intake. The outcomes of interest were whether action was
currently being taken by the subject to follow that past advice.
RESULTS: After controlling potential confounders (including
demographics, education, and disease severity), it was found that
subjects who were told by their doctor or health professional to
lose weight were more likely to be working on weight control,
compared with those not told to do so (p < 0.001). Similar results
were found for exercise advice (p = 0.001) and diet advice
(p = 0.002). This cross-sectional analysis cannot conﬁrm causal-
ity and recall bias cannot be eliminated. CONCLUSION: The
study suggests that advice by a doctor or a health professional
has great impact on diabetic patients to take actions in changing
their lifestyle behaviors.
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CONTRIBUTETO IDS SATISFACTION IN PATIENTSWITH
TYPE 2 DIABETES
Yang HK1, Hayes RP2, Boye KS2
1University of Maryland Baltimore, Baltimore, MD, USA, 2Eli Lilly and
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OBJECTIVE: Differences between patient-rated importance of
insulin delivery system (IDS) features and patient evaluation of
those features in current IDS may contribute to patient satisfac-
tion. This study aimed to examine: 1) the importance of 12 IDS
features to patients with type 2 diabetes (T2DM); 2) the dis-
crepancies between feature importance and patient evaluation
of those features in current IDS; 3) the relationship between
discrepancies and IDS satisfaction. METHODS: Patients with
T2DM currently using insulin were administered a web-based
survey including questions on demographics, insulin therapy, and
a modiﬁed Insulin Injection Preference questionnaire (mIIP-q).
ThemIIP-q asks patients to evaluate the extent towhich they agree
their current IDS has each of the 12 features representing 3
components (“ease of use,” “activity interference,” and “social
acceptability”). Patients were also asked to rank and rate the
importance of the 12 IDS features. Discrepancy scores were
calculated by subtracting the feature importance score from the
feature evaluation score. Correlation and stepwise linear regres-
sion analyses were conducted to assess the relationship between
discrepancy scores and IDS satisfaction.RESULTS:A total of 681
patients (48%male, mean age = 57) participated in the survey. All
IDS features in the mIIP-q were considered important (mean
rating >50 on a 0–100 scale). The feature “easy to control blood
sugar” showed the highest discrepancy score, followed by all
“activity interference” features (P < 0.01). Discrepancy scores for
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